Expression profiling of tumor cells from MYCN-driven neuroblastoma upon BRD4 or AURKA inhibition

ABSTRACT: Amplification of MYCN is the most prominent genetic marker of high-stage neuroblastoma, a childhood tumor originating from the neural crest. We generated a cell line (mNB-A1) from tumors developed in transgenic mouse and treated these cells with DMSO (n=6), the BRD4-inhibitor JQ1 (n=3) or the AURKA-inhibitor MLN8237 (n=3) for 24 h.

ORGANISM(S): Mus musculus

PROVIDER: GSE57810 | GEO | 2014/09/01

SECONDARY ACCESSION(S): PRJNA248139

REPOSITORIES: GEO